Stay updated on Pembrolizumab Post-Tx in Oligometastatic NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Post-Tx in Oligometastatic NSCLC Clinical Trial page.

Latest updates to the Pembrolizumab Post-Tx in Oligometastatic NSCLC Clinical Trial page
- Check4 days agoChange DetectedA dedicated Locations section now lists Pennsylvania as the study site, replacing the prior Pennsylvania Locations entry. The footer's HHS Vulnerability Disclosure was removed and the revision updated to v3.3.3.SummaryDifference0.3%

- Check12 days agoNo Change Detected
- Check19 days agoNo Change Detected
- Check33 days agoChange DetectedRevision tag updated from v3.2.0 to v3.3.2; no study information or eligibility details appear to be altered.SummaryDifference0.1%

- Check40 days agoChange DetectedThe funding and operating status banner was removed from the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check48 days agoChange DetectedTimestamp-related label updates and new date references (e.g., 'Last Update Posted (Estimated)' and 2025-11 dates) were added; these adjustments do not modify the study details, eligibility criteria, or results. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check62 days agoChange DetectedThe new screenshot shows an updated last update date and minor formatting adjustments; core study details appear unchanged.SummaryDifference0.5%

- Check83 days agoChange Detected- Added a government funding notice and operating status guidance, and added version 3.2.0. - Removed version 3.1.0.SummaryDifference4%

Stay in the know with updates to Pembrolizumab Post-Tx in Oligometastatic NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Post-Tx in Oligometastatic NSCLC Clinical Trial page.